Do analysts prefer ENVB or NNVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable valuation and earnings, ENVB or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enveric Biosciences N/A N/A -$8.77M -$23.54 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is ENVB or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -220.97% -177.47% NanoViricides N/A -87.90% -78.69%

Do analysts recommend ENVB or SCYX?

SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 391.80%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer ENVB or SCYX?

In the previous week, Enveric Biosciences and Enveric Biosciences both had 1 articles in the media. Enveric Biosciences' average media sentiment score of 0.94 beat SCYNEXIS's score of 0.93 indicating that Enveric Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer APLM or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, APLM or ENVB?

Enveric Biosciences has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 3.62 -$10.94M N/A N/A Enveric Biosciences N/A N/A -$8.77M -$23.54 N/A

Is APLM or ENVB more profitable?

Apollomics' return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Enveric Biosciences N/A -220.97% -177.47%

Do analysts rate ENVB or CPHI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to ENVB or CPHI?

In the previous week, Enveric Biosciences and Enveric Biosciences both had 1 articles in the media. Enveric Biosciences' average media sentiment score of 0.94 beat China Pharma's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SNTI or ENVB?

Senti Biosciences presently has a consensus price target of $8.75, suggesting a potential upside of 775.00%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Senti Biosciences is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SNTI or ENVB more profitable?

Enveric Biosciences' return on equity of -220.97% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% Enveric Biosciences N/A -220.97% -177.47%

Enveric Biosciences (ENVB) Competitors

$1.96 -0.02 (-1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$1.96 +0.01 (+0.26%)

As of 04:10 PM Eastern

Compare

ENVB vs. NNVC, SCYX, APLM, CPHI, and SNTI

Should you buy Enveric Biosciences stock or one of its competitors? MarketBeat compares Enveric Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enveric Biosciences include NanoViricides (NNVC), SCYNEXIS (SCYX), Apollomics (APLM), China Pharma (CPHI), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry.

How does Enveric Biosciences compare to NanoViricides?

Enveric Biosciences (NASDAQ:ENVB) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Enveric Biosciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

In the previous week, Enveric Biosciences had 1 more articles in the media than NanoViricides. MarketBeat recorded 1 mentions for Enveric Biosciences and 0 mentions for NanoViricides. Enveric Biosciences' average media sentiment score of 0.94 beat NanoViricides' score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Enveric Biosciences	Positive
NanoViricides	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

NanoViricides' return on equity of -87.90% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
NanoViricides	N/A	-87.90%	-78.69%

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Comparatively, 3.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NanoViricides is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Summary

NanoViricides beats Enveric Biosciences on 8 of the 12 factors compared between the two stocks.

How does Enveric Biosciences compare to SCYNEXIS?

Enveric Biosciences (NASDAQ:ENVB) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Enveric Biosciences has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Enveric Biosciences has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

In the previous week, Enveric Biosciences and Enveric Biosciences both had 1 articles in the media. Enveric Biosciences' average media sentiment score of 0.94 beat SCYNEXIS's score of 0.93 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enveric Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 391.80%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SCYNEXIS has higher revenue and earnings than Enveric Biosciences. SCYNEXIS is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
SCYNEXIS	$20.60M	1.32	-$8.61M	-$3.84	N/A

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by company insiders. Comparatively, 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

SCYNEXIS beats Enveric Biosciences on 10 of the 14 factors compared between the two stocks.

How does Enveric Biosciences compare to Apollomics?

Apollomics (NASDAQ:APLM) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Enveric Biosciences had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for Enveric Biosciences and 0 mentions for Apollomics. Apollomics' average media sentiment score of 1.87 beat Enveric Biosciences' score of 0.94 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Very Positive
Enveric Biosciences	Positive

Apollomics' return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Enveric Biosciences	N/A	-220.97%	-177.47%

19.1% of Apollomics shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Enveric Biosciences has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.62	-$10.94M	N/A	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

Summary

Apollomics beats Enveric Biosciences on 6 of the 9 factors compared between the two stocks.

How does Enveric Biosciences compare to China Pharma?

Enveric Biosciences (NASDAQ:ENVB) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

13.8% of Enveric Biosciences shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Enveric Biosciences has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
China Pharma	-85.56%	-63.93%	-31.42%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

China Pharma has higher revenue and earnings than Enveric Biosciences. China Pharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
China Pharma	$3.99M	8.57	-$3.08M	-$0.55	N/A

In the previous week, Enveric Biosciences and Enveric Biosciences both had 1 articles in the media. Enveric Biosciences' average media sentiment score of 0.94 beat China Pharma's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enveric Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enveric Biosciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Summary

China Pharma beats Enveric Biosciences on 7 of the 12 factors compared between the two stocks.

How does Enveric Biosciences compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Enveric Biosciences' return on equity of -220.97% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Enveric Biosciences	N/A	-220.97%	-177.47%

Senti Biosciences presently has a consensus price target of $8.75, suggesting a potential upside of 775.00%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Senti Biosciences is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Enveric Biosciences had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 1 mentions for Enveric Biosciences and 0 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 1.89 beat Enveric Biosciences' score of 0.94 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Very Positive
Enveric Biosciences	Positive

Senti Biosciences has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Enveric Biosciences has lower revenue, but higher earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,557.50	-$61.44M	-$1.92	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

Summary

Senti Biosciences beats Enveric Biosciences on 11 of the 15 factors compared between the two stocks.

Get Enveric Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENVB vs. The Competition

Export

Metric	Enveric Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.21M	$3.35B	$6.44B	$12.47B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.08	18.72	23.87	24.40
Price / Sales	N/A	320.32	521.86	117.01
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.28	6.80	9.99	6.73
Net Income	-$8.77M	$24.09M	$3.56B	$337.03M
7 Day Performance	-15.52%	-2.48%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	-87.34%	48.95%	28.77%	34.24%

Enveric Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENVB Enveric Biosciences	1.1132 of 5 stars	$1.96 -1.0%	N/A	-87.0%	$7.21M	N/A	N/A	20
NNVC NanoViricides	0.1805 of 5 stars	$1.51 -7.9%	N/A	+2.7%	$32.69M	N/A	N/A	20	High Trading Volume
SCYX SCYNEXIS	2.1532 of 5 stars	$0.68 -6.9%	$3.00 +340.5%	-33.9%	$32.66M	$20.60M	N/A	60
APLM Apollomics	1.1933 of 5 stars	$14.09 -1.5%	N/A	+115.7%	$30.93M	$8.50M	N/A	45
CPHI China Pharma	N/A	$0.76 +0.0%	N/A	-46.0%	$30.80M	$3.99M	N/A	250

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENVB) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enveric Biosciences (ENVB) Competitors

ENVB vs. NNVC, SCYX, APLM, CPHI, and SNTI

How does Enveric Biosciences compare to NanoViricides?

Summary

How does Enveric Biosciences compare to SCYNEXIS?

Summary

How does Enveric Biosciences compare to Apollomics?

Summary

How does Enveric Biosciences compare to China Pharma?

Summary

How does Enveric Biosciences compare to Senti Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enveric Biosciences (ENVB) Competitors

ENVB vs. NNVC, SCYX, APLM, CPHI, and SNTI

How does Enveric Biosciences compare to NanoViricides?

Which has more volatility and risk, ENVB or NNVC?

Does the media prefer ENVB or NNVC?

Do analysts prefer ENVB or NNVC?

Is ENVB or NNVC more profitable?

Do insiders & institutionals hold more shares of ENVB or NNVC?

Which has preferable valuation and earnings, ENVB or NNVC?

Summary

How does Enveric Biosciences compare to SCYNEXIS?

Is ENVB or SCYX more profitable?

Which has more risk & volatility, ENVB or SCYX?

Does the media prefer ENVB or SCYX?

Do analysts recommend ENVB or SCYX?

Which has preferable valuation & earnings, ENVB or SCYX?

Do insiders and institutionals believe in ENVB or SCYX?

Summary

How does Enveric Biosciences compare to Apollomics?

Which has more volatility and risk, APLM or ENVB?

Does the media favor APLM or ENVB?

Is APLM or ENVB more profitable?

Do institutionals & insiders hold more shares of APLM or ENVB?

Do analysts prefer APLM or ENVB?

Which has higher valuation & earnings, APLM or ENVB?

Summary

How does Enveric Biosciences compare to China Pharma?

Do insiders and institutionals believe in ENVB or CPHI?

Is ENVB or CPHI more profitable?

Do analysts rate ENVB or CPHI?

Which has preferable valuation & earnings, ENVB or CPHI?

Does the media refer more to ENVB or CPHI?

Which has more volatility & risk, ENVB or CPHI?

Summary

How does Enveric Biosciences compare to Senti Biosciences?

Do insiders and institutionals hold more shares of SNTI or ENVB?

Is SNTI or ENVB more profitable?

Do analysts rate SNTI or ENVB?

Does the media prefer SNTI or ENVB?

Which has more risk and volatility, SNTI or ENVB?

Which has preferable valuation & earnings, SNTI or ENVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools